Clinical Trial Update: A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms [Phase 2, Phase 3]

View source ↗

Summary

This is a clinical trial update for a Phase 2/3 study of Lutetium-177 DOTATATE in patients with advanced neuroendocrine neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasms

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Advanced Neuroendocrine Neoplasm | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING